These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31445162)

  • 1. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.
    Schofield DJ; Irving L; Calo L; Bogstedt A; Rees G; Nuccitelli A; Narwal R; Petrone M; Roberts J; Brown L; Cusdin F; Dosanjh B; Lloyd C; Dobson C; Gurrell I; Fraser G; McFarlane M; Rockenstein E; Spencer B; Masliah E; Spillantini MG; Tan K; Billinton A; Vaughan T; Chessell I; Perkinton MS
    Neurobiol Dis; 2019 Dec; 132():104582. PubMed ID: 31445162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.
    Weihofen A; Liu Y; Arndt JW; Huy C; Quan C; Smith BA; Baeriswyl JL; Cavegn N; Senn L; Su L; Marsh G; Auluck PK; Montrasio F; Nitsch RM; Hirst WD; Cedarbaum JM; Pepinsky RB; Grimm J; Weinreb PH
    Neurobiol Dis; 2019 Apr; 124():276-288. PubMed ID: 30381260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel naturally occurring autoantibodies attenuate α-synuclein pathology in a mouse model of Parkinson's disease.
    Li Y; Wang T; Meng L; Jin L; Liu C; Liang Y; Ren L; Liu Y; Liu Y; Liu S; Li T; Liang Y; Chen X; Zhang Z
    Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12860. PubMed ID: 36331758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron reduces the propagation of pathological α-synuclein: An Editorial Highlight for "Brain iron enrichment attenuates α-synuclein spreading after injection of preformed fibrils" on page 554.
    Guo YJ; Ayton S; Lei P
    J Neurochem; 2021 Nov; 159(3):414-416. PubMed ID: 34296424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular clusterin limits the uptake of α-synuclein fibrils by murine and human astrocytes.
    Filippini A; Mutti V; Faustini G; Longhena F; Ramazzina I; Rizzi F; Kaganovich A; Roosen DA; Landeck N; Duffy M; Tessari I; Bono F; Fiorentini C; Greggio E; Bubacco L; Bellucci A; Missale M; Cookson MR; Gennarelli M; Russo I
    Glia; 2021 Mar; 69(3):681-696. PubMed ID: 33045109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson's Disease.
    Menéndez-González M; Padilla-Zambrano HS; Tomás-Zapico C; García BF
    Brain Sci; 2018 Mar; 8(4):. PubMed ID: 29570693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propagation of pathological α-synuclein in marmoset brain.
    Shimozawa A; Ono M; Takahara D; Tarutani A; Imura S; Masuda-Suzukake M; Higuchi M; Yanai K; Hisanaga SI; Hasegawa M
    Acta Neuropathol Commun; 2017 Feb; 5(1):12. PubMed ID: 28148299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.
    Tran HT; Chung CH; Iba M; Zhang B; Trojanowski JQ; Luk KC; Lee VM
    Cell Rep; 2014 Jun; 7(6):2054-65. PubMed ID: 24931606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.
    Games D; Valera E; Spencer B; Rockenstein E; Mante M; Adame A; Patrick C; Ubhi K; Nuber S; Sacayon P; Zago W; Seubert P; Barbour R; Schenk D; Masliah E
    J Neurosci; 2014 Jul; 34(28):9441-54. PubMed ID: 25009275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease.
    Nordström E; Eriksson F; Sigvardson J; Johannesson M; Kasrayan A; Jones-Kostalla M; Appelkvist P; Söderberg L; Nygren P; Blom M; Rachalski A; Nordenankar K; Zachrisson O; Amandius E; Osswald G; Moge M; Ingelsson M; Bergström J; Lannfelt L; Möller C; Giorgetti M; Fälting J
    Neurobiol Dis; 2021 Dec; 161():105543. PubMed ID: 34737044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition and knockdown of O-GlcNAcase reduces cellular internalization of α-synuclein preformed fibrils.
    Tavassoly O; Yue J; Vocadlo DJ
    FEBS J; 2021 Jan; 288(2):452-470. PubMed ID: 32365408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.
    Li X; Koudstaal W; Fletcher L; Costa M; van Winsen M; Siregar B; Inganäs H; Kim J; Keogh E; Macedo J; Holland T; Perry S; Bard F; Hoozemans JJ; Goudsmit J; Apetri A; Pascual G
    Acta Neuropathol; 2019 May; 137(5):825-836. PubMed ID: 30805666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies against alpha-synuclein: tools and therapies.
    Vaikath NN; Hmila I; Gupta V; Erskine D; Ingelsson M; El-Agnaf OMA
    J Neurochem; 2019 Sep; 150(5):612-625. PubMed ID: 31055836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-α-synuclein c-terminal antibodies block PFF uptake and accumulation of phospho-synuclein in preclinical models of Parkinson's disease.
    Brendza R; Gao X; Stark KL; Lin H; Lee SH; Hu C; Cai H; DiCara D; Hsiao YC; Ngu H; Foreman O; Baca M; Dohse M; Fortin JP; Corpuz R; Seshasayee D; Easton A; Ayalon G; Hötzel I; Chih B
    Neurobiol Dis; 2023 Feb; 177():105969. PubMed ID: 36535551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous Levels of Alpha-Synuclein Modulate Seeding and Aggregation in Cultured Cells.
    Vasili E; Dominguez-Meijide A; Flores-León M; Al-Azzani M; Kanellidi A; Melki R; Stefanis L; Outeiro TF
    Mol Neurobiol; 2022 Feb; 59(2):1273-1284. PubMed ID: 34984585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease.
    Henderson MX; Covell DJ; Chung CH; Pitkin RM; Sandler RM; Decker SC; Riddle DM; Zhang B; Gathagan RJ; James MJ; Trojanowski JQ; Brunden KR; Lee VMY; Luk KC
    Neurobiol Dis; 2020 Mar; 136():104712. PubMed ID: 31837422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotaxic Targeting of Alpha-Synuclein Pathology in Mouse Brain Using Preformed Fibrils.
    Zhang B; Kehm V; Gathagan R; Leight SN; Trojanowski JQ; Lee VM; Luk KC
    Methods Mol Biol; 2019; 1948():45-57. PubMed ID: 30771169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.